| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oligonucleotides, Antisense | 19 | 2025 | 154 | 6.580 |
Why?
|
| Oligonucleotides | 21 | 2025 | 229 | 4.330 |
Why?
|
| RNA, Small Interfering | 15 | 2026 | 990 | 2.860 |
Why?
|
| Gene Editing | 11 | 2025 | 331 | 2.250 |
Why?
|
| RNA | 11 | 2026 | 427 | 2.200 |
Why?
|
| Gene Silencing | 12 | 2026 | 436 | 2.090 |
Why?
|
| Nucleic Acids | 2 | 2022 | 67 | 1.220 |
Why?
|
| RNA Interference | 9 | 2026 | 647 | 1.080 |
Why?
|
| CRISPR-Cas Systems | 6 | 2025 | 369 | 1.000 |
Why?
|
| RNA, Double-Stranded | 6 | 2020 | 113 | 0.980 |
Why?
|
| Brain Neoplasms | 3 | 2024 | 319 | 0.940 |
Why?
|
| DNA | 11 | 2025 | 853 | 0.930 |
Why?
|
| Glioblastoma | 2 | 2024 | 161 | 0.920 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 203 | 0.830 |
Why?
|
| Fibroblasts | 4 | 2022 | 423 | 0.820 |
Why?
|
| RNA, Messenger | 6 | 2026 | 1581 | 0.820 |
Why?
|
| Friedreich Ataxia | 2 | 2022 | 8 | 0.790 |
Why?
|
| RNA, Long Noncoding | 3 | 2024 | 170 | 0.760 |
Why?
|
| Genetic Therapy | 5 | 2025 | 852 | 0.740 |
Why?
|
| Splints | 1 | 2021 | 6 | 0.710 |
Why?
|
| RNA Splicing | 5 | 2026 | 173 | 0.690 |
Why?
|
| Arabinonucleotides | 3 | 2010 | 4 | 0.690 |
Why?
|
| Gene Expression Regulation | 6 | 2022 | 1634 | 0.680 |
Why?
|
| Animals | 28 | 2026 | 21467 | 0.670 |
Why?
|
| Mice | 17 | 2026 | 11174 | 0.660 |
Why?
|
| Phenotype | 1 | 2024 | 1235 | 0.650 |
Why?
|
| Endothelial Cells | 1 | 2022 | 215 | 0.650 |
Why?
|
| Proprotein Convertase 9 | 1 | 2020 | 15 | 0.620 |
Why?
|
| Acetylgalactosamine | 2 | 2024 | 13 | 0.600 |
Why?
|
| Peptide Nucleic Acids | 2 | 2018 | 17 | 0.600 |
Why?
|
| Lung | 3 | 2023 | 969 | 0.580 |
Why?
|
| Drug Delivery Systems | 4 | 2022 | 333 | 0.570 |
Why?
|
| Triazoles | 2 | 2018 | 63 | 0.540 |
Why?
|
| Humans | 43 | 2026 | 65650 | 0.530 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 108 | 0.520 |
Why?
|
| RNAi Therapeutics | 1 | 2017 | 12 | 0.510 |
Why?
|
| Monosaccharides | 2 | 2007 | 7 | 0.490 |
Why?
|
| Uridine | 2 | 2007 | 23 | 0.490 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2025 | 517 | 0.440 |
Why?
|
| Cells, Cultured | 5 | 2022 | 2193 | 0.430 |
Why?
|
| Antiviral Agents | 2 | 2023 | 330 | 0.410 |
Why?
|
| Phosphorothioate Oligonucleotides | 2 | 2024 | 10 | 0.400 |
Why?
|
| Organophosphorus Compounds | 3 | 2023 | 33 | 0.390 |
Why?
|
| Cytidine Deaminase | 2 | 2025 | 86 | 0.380 |
Why?
|
| Central Nervous System | 2 | 2024 | 200 | 0.370 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 872 | 0.360 |
Why?
|
| Frontotemporal Dementia | 2 | 2025 | 158 | 0.350 |
Why?
|
| Iron-Binding Proteins | 2 | 2022 | 12 | 0.320 |
Why?
|
| Thermodynamics | 2 | 2010 | 197 | 0.320 |
Why?
|
| Zebrafish | 2 | 2025 | 374 | 0.310 |
Why?
|
| RNA, Antisense | 1 | 2010 | 51 | 0.310 |
Why?
|
| Alternative Splicing | 2 | 2026 | 140 | 0.310 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 1573 | 0.300 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 196 | 0.300 |
Why?
|
| Liver | 4 | 2024 | 874 | 0.290 |
Why?
|
| Organoselenium Compounds | 1 | 2008 | 3 | 0.280 |
Why?
|
| Oligoribonucleotides | 1 | 2008 | 16 | 0.280 |
Why?
|
| Aptamers, Nucleotide | 2 | 2021 | 27 | 0.280 |
Why?
|
| DNA-Binding Proteins | 2 | 2025 | 1226 | 0.270 |
Why?
|
| Enzyme Inhibitors | 2 | 2025 | 371 | 0.260 |
Why?
|
| Genome, Human | 2 | 2021 | 238 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 689 | 0.260 |
Why?
|
| RNA Splice Sites | 1 | 2026 | 24 | 0.240 |
Why?
|
| Dysferlin | 1 | 2026 | 15 | 0.240 |
Why?
|
| Precision Medicine | 2 | 2025 | 134 | 0.240 |
Why?
|
| Morpholinos | 1 | 2026 | 55 | 0.240 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2026 | 25 | 0.240 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2026 | 225 | 0.230 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2025 | 4 | 0.230 |
Why?
|
| RNA Precursors | 1 | 2026 | 80 | 0.230 |
Why?
|
| Base Sequence | 7 | 2022 | 1331 | 0.230 |
Why?
|
| Nanoparticles | 3 | 2021 | 552 | 0.230 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2026 | 72 | 0.230 |
Why?
|
| Genome | 2 | 2025 | 286 | 0.220 |
Why?
|
| Gene Knock-In Techniques | 1 | 2025 | 48 | 0.220 |
Why?
|
| Models, Molecular | 4 | 2021 | 1159 | 0.220 |
Why?
|
| Rare Diseases | 1 | 2025 | 45 | 0.220 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2025 | 53 | 0.220 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2024 | 23 | 0.210 |
Why?
|
| Trinucleotide Repeat Expansion | 3 | 2023 | 36 | 0.210 |
Why?
|
| Deoxyribonucleotides | 1 | 2024 | 13 | 0.210 |
Why?
|
| Molecular Conformation | 3 | 2017 | 114 | 0.210 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2024 | 39 | 0.210 |
Why?
|
| Ribonuclease H | 2 | 2018 | 19 | 0.210 |
Why?
|
| Motor Neurons | 1 | 2025 | 219 | 0.210 |
Why?
|
| C9orf72 Protein | 2 | 2022 | 115 | 0.210 |
Why?
|
| DNA, Single-Stranded | 2 | 2022 | 109 | 0.210 |
Why?
|
| Information Dissemination | 1 | 2025 | 114 | 0.200 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2024 | 119 | 0.200 |
Why?
|
| Adenine | 1 | 2024 | 48 | 0.200 |
Why?
|
| Mice, Nude | 1 | 2024 | 287 | 0.200 |
Why?
|
| Technology | 1 | 2023 | 53 | 0.200 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2023 | 17 | 0.200 |
Why?
|
| Peptides | 2 | 2026 | 593 | 0.200 |
Why?
|
| Drug Design | 2 | 2017 | 138 | 0.190 |
Why?
|
| Endonucleases | 1 | 2023 | 84 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 196 | 0.190 |
Why?
|
| Fragile X Syndrome | 1 | 2023 | 29 | 0.190 |
Why?
|
| DNA Repair | 2 | 2021 | 263 | 0.190 |
Why?
|
| Trachea | 1 | 2022 | 83 | 0.180 |
Why?
|
| Motor Activity | 1 | 2024 | 346 | 0.180 |
Why?
|
| Disease Models, Animal | 3 | 2026 | 2327 | 0.170 |
Why?
|
| Trypsin | 1 | 2021 | 43 | 0.170 |
Why?
|
| Endoribonucleases | 1 | 2021 | 57 | 0.170 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 211 | 0.170 |
Why?
|
| Cells | 1 | 2021 | 32 | 0.160 |
Why?
|
| Chromatids | 1 | 2020 | 15 | 0.160 |
Why?
|
| Chromosome Segregation | 1 | 2020 | 43 | 0.160 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 117 | 0.160 |
Why?
|
| Mutation | 3 | 2026 | 2672 | 0.160 |
Why?
|
| Germany | 1 | 2019 | 57 | 0.150 |
Why?
|
| Circular Dichroism | 3 | 2010 | 108 | 0.150 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1389 | 0.140 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2018 | 3 | 0.140 |
Why?
|
| Water | 2 | 2010 | 317 | 0.140 |
Why?
|
| Transcription Factor 4 | 1 | 2018 | 3 | 0.140 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2018 | 4 | 0.140 |
Why?
|
| Macromolecular Substances | 1 | 2018 | 162 | 0.130 |
Why?
|
| Chromatin | 2 | 2020 | 643 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 175 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2018 | 226 | 0.120 |
Why?
|
| Nucleosides | 2 | 2007 | 11 | 0.120 |
Why?
|
| Introns | 3 | 2026 | 114 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 129 | 0.120 |
Why?
|
| Nucleic Acid Conformation | 3 | 2020 | 241 | 0.120 |
Why?
|
| Escherichia coli | 1 | 2021 | 717 | 0.120 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 65 | 0.120 |
Why?
|
| ADAM Proteins | 1 | 2016 | 36 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 308 | 0.120 |
Why?
|
| Cell Membrane | 1 | 2018 | 506 | 0.110 |
Why?
|
| Molecular Imprinting | 1 | 2014 | 6 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 807 | 0.110 |
Why?
|
| Binding Sites | 1 | 2017 | 921 | 0.110 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 708 | 0.110 |
Why?
|
| Alleles | 2 | 2018 | 455 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2015 | 133 | 0.100 |
Why?
|
| RNA Polymerase II | 2 | 2014 | 86 | 0.100 |
Why?
|
| Male | 6 | 2025 | 31295 | 0.100 |
Why?
|
| Exons | 2 | 2026 | 208 | 0.100 |
Why?
|
| Nucleic Acid Denaturation | 2 | 2010 | 7 | 0.100 |
Why?
|
| Models, Genetic | 1 | 2014 | 267 | 0.100 |
Why?
|
| Cations | 2 | 2011 | 64 | 0.100 |
Why?
|
| Catalytic Domain | 2 | 2025 | 198 | 0.100 |
Why?
|
| Hydrogen Bonding | 2 | 2010 | 128 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2026 | 316 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2011 | 315 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2024 | 714 | 0.090 |
Why?
|
| Spermine | 1 | 2011 | 3 | 0.090 |
Why?
|
| Neurons | 3 | 2025 | 935 | 0.080 |
Why?
|
| Polymers | 1 | 2014 | 332 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2018 | 1559 | 0.080 |
Why?
|
| Fluorine | 1 | 2010 | 9 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 112 | 0.080 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 85 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2010 | 105 | 0.070 |
Why?
|
| Crotalus | 1 | 2009 | 1 | 0.070 |
Why?
|
| 2',3'-Cyclic-Nucleotide Phosphodiesterases | 1 | 2009 | 3 | 0.070 |
Why?
|
| Viper Venoms | 1 | 2009 | 2 | 0.070 |
Why?
|
| Alkalies | 1 | 2009 | 4 | 0.070 |
Why?
|
| Acids | 1 | 2009 | 14 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2009 | 52 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 333 | 0.070 |
Why?
|
| Hydrolysis | 1 | 2009 | 146 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2011 | 351 | 0.070 |
Why?
|
| Catalysis | 1 | 2009 | 164 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 462 | 0.070 |
Why?
|
| Biophysical Phenomena | 1 | 2008 | 23 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 234 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 100 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 428 | 0.070 |
Why?
|
| Research Design | 1 | 2011 | 590 | 0.070 |
Why?
|
| Biophysics | 1 | 2008 | 42 | 0.070 |
Why?
|
| Nucleotides | 1 | 2008 | 48 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2021 | 617 | 0.070 |
Why?
|
| Carbohydrate Conformation | 1 | 2007 | 17 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 792 | 0.060 |
Why?
|
| Spliceosomes | 1 | 2026 | 44 | 0.060 |
Why?
|
| Glycosylation | 1 | 2006 | 139 | 0.060 |
Why?
|
| Recombinational DNA Repair | 1 | 2025 | 29 | 0.060 |
Why?
|
| Injections, Spinal | 1 | 2025 | 44 | 0.060 |
Why?
|
| Cytidine | 1 | 2025 | 15 | 0.060 |
Why?
|
| APOBEC Deaminases | 1 | 2025 | 11 | 0.060 |
Why?
|
| Phosphates | 1 | 2026 | 104 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 278 | 0.050 |
Why?
|
| Moloney murine leukemia virus | 1 | 2024 | 17 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2025 | 89 | 0.050 |
Why?
|
| Antagomirs | 1 | 2024 | 5 | 0.050 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2025 | 160 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2024 | 115 | 0.050 |
Why?
|
| Templates, Genetic | 1 | 2023 | 24 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 292 | 0.050 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2022 | 21 | 0.050 |
Why?
|
| Transcriptome | 1 | 2026 | 405 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2026 | 634 | 0.050 |
Why?
|
| Biotinylation | 1 | 2022 | 36 | 0.040 |
Why?
|
| Dipeptides | 1 | 2022 | 69 | 0.040 |
Why?
|
| Biotin | 1 | 2022 | 54 | 0.040 |
Why?
|
| K562 Cells | 1 | 2021 | 59 | 0.040 |
Why?
|
| Cell-Free System | 1 | 2021 | 32 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 588 | 0.040 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2021 | 21 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2022 | 257 | 0.040 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 32 | 0.040 |
Why?
|
| Serum Albumin, Bovine | 1 | 2021 | 35 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 408 | 0.040 |
Why?
|
| Muramidase | 1 | 2021 | 47 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 2022 | 116 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2026 | 788 | 0.040 |
Why?
|
| G-Quadruplexes | 1 | 2020 | 7 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2030 | 0.040 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2020 | 25 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 96 | 0.040 |
Why?
|
| Female | 4 | 2025 | 34309 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 126 | 0.040 |
Why?
|
| Mitosis | 1 | 2020 | 222 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2021 | 278 | 0.030 |
Why?
|
| Particle Size | 1 | 2020 | 432 | 0.030 |
Why?
|
| DNA Replication | 1 | 2020 | 250 | 0.030 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2018 | 2 | 0.030 |
Why?
|
| Endothelium, Corneal | 1 | 2018 | 5 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1291 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2018 | 117 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 80 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 426 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 100 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 281 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3501 | 0.030 |
Why?
|
| Proteins | 1 | 2022 | 764 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1487 | 0.030 |
Why?
|
| Aged | 2 | 2025 | 15089 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2020 | 573 | 0.030 |
Why?
|
| Adult | 2 | 2025 | 17511 | 0.030 |
Why?
|
| Middle Aged | 2 | 2025 | 18439 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 526 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2025 | 5820 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 735 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 206 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2011 | 40 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 52 | 0.020 |
Why?
|
| Ataxin-3 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Transition Temperature | 1 | 2010 | 6 | 0.020 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2010 | 29 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2010 | 19 | 0.020 |
Why?
|
| Interferons | 1 | 2010 | 74 | 0.020 |
Why?
|
| RNA Stability | 1 | 2010 | 104 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2010 | 224 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 325 | 0.020 |
Why?
|
| Child | 1 | 2018 | 4634 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1979 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 5656 | 0.020 |
Why?
|
| United States | 1 | 2021 | 8166 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 404 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 441 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 6350 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1193 | 0.010 |
Why?
|